DOAC - Dosing Options in AntiCoagulation Prophylaxis for Cancer Patients
Blood clots (venous thromboembolism or VTE) are a serious concern for people with cancer. This study is testing different ways to use a blood thinner called apixaban (Eliquis) to prevent these clots in cancer patients who are at moderate risk. You might be eligible if you are 18 or older, have a solid tumor or lymphoma, are starting or changing cancer treatment, and have a specific risk score (Khorana Risk Score of 2). The study will compare three groups: one receiving apixaban 2.5 mg twice daily, another receiving apixaban 5 mg once daily, and a third group receiving no blood thinner. The main goal is to see if apixaban can reduce the number of blood clots in these groups over 6 months compared to not taking a blood thinner. The study is currently unclear on its recruitment status and plans to enroll 996 participants.
- Study design
- This is an interventional study with an unspecified phase, comparing three different treatment approaches in approximately 996 participants.
- What's involved
- Participants in the apixaban arms will take the medication by mouth for 6 months. All participants will have their outcomes monitored through routine care and medical records.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants will be followed for 6 months to measure the incidence of VTE.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
DOAC - Dosing Options in AntiCoagulation Prophylaxis
At a glance
Conditions
NCT07005024
Where you'd take part
This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
University of Vermont Medical Center
Burlington, Vermontstudy coordinator listed
Recruiting
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Want this trial checked against your situation?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
Exclusion
What this trial measures
- Incidence of VTE in Participants Receiving Apixaban 2.5 mg Twice Daily vs No Anticoagulation6 months
This outcome compares the incidence of venous thromboembolism (VTE) - including deep vein thrombosis, pulmonary embolism, and other clinically relevant thromboses - between participants receiving apixaban 2.5 mg BID and those receiving no anticoagulation prophylaxis. Events will be identified through clinical care and confirmed via chart review. Both symptomatic and incidental VTEs will be included.
- Incidence of VTE in Participants Receiving Apixaban 5 mg Once Daily vs No Anticoagulation6 months
This outcome compares the incidence of venous thromboembolism (VTE) between participants randomized to apixaban 5 mg once daily and those receiving no anticoagulation. VTEs may include DVT, PE, or other thromboses, whether symptomatic or incidental. Events will be confirmed through medical record review. The goal is to determine whether this simplified dosing schedule provides effective VTE prevention in cancer patients with Khorana Risk Score of 2.